Atacand and Metastatic neoplasm - a phase IV clinical study of FDA data

Summary:

Metastatic neoplasm is reported as a side effect among people who take Atacand (candesartan cilexetil), especially for people who are female, 60+ old, have been taking the drug for 2 - 5 years also take Prevacid, and have Breast cancer metastatic.

The phase IV clinical study analyzes which people have Metastatic neoplasm when taking Atacand. It is created by eHealthMe based on reports of 21,732 people who have side effects when taking Atacand from the FDA, and is updated regularly.

What is Atacand?

Atacand has active ingredients of candesartan cilexetil. It is often used in high blood pressure. eHealthMe is studying from 22,473 Atacand users. Check the latest studies of Atacand.

What is Metastatic neoplasm?

Metastatic neoplasm (spreadable cancer tumour) is found to be associated with 601 drugs and 516 conditions by eHealthMe. Check the latest studies of Metastatic neoplasm.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

21,732 people reported to have side effects when taking Atacand.
Among them, 17 people (0.08%) have Metastatic neoplasm.

Could Atacand cause Metastatic neoplasm?

Among these 17 people:

How long have people been on Atacand when they have Metastatic neoplasm? *

What is the gender of people who have Metastatic neoplasm when taking Atacand? *

female: 82.35 %
male: 17.65 %

What is the age of people who have Metastatic neoplasm when taking Atacand? *

What are other drugs people take besides Atacand? *

What are other side effects people have besides Metastatic neoplasm? *

Abdominal Pain: 10 people, 58.82%
Death: 10 people, 58.82%
Osteopenia (a condition where bone mineral density is lower than normal): 8 people, 47.06%
Metastases To Bone (cancer spreads to bone): 8 people, 47.06%
Osteoporosis (bones weak and more likely to break): 8 people, 47.06%
Osteonecrosis Of Jaw (death of bone of jaw): 8 people, 47.06%
Osteomyelitis (infection of bone): 8 people, 47.06%
Oedema Peripheral (superficial swelling): 8 people, 47.06%
Oedema (fluid collection in tissue): 8 people, 47.06%
Nausea And Vomiting: 8 people, 47.06%

What are the existing conditions these people have? *

Breast Cancer Metastatic: 7 people, 41.18%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 11.76%
Colon Cancer: 2 people, 11.76%
Type 2 Diabetes: 1 person, 5.88%
High Blood Cholesterol: 1 person, 5.88%
Gastroparesis (delayed emptying of food from the stomach): 1 person, 5.88%
Birth Control: 1 person, 5.88%
Anaemia (lack of blood): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Atacand and have Metastatic neoplasm?

- Check whether Metastatic neoplasm is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Atacand:

Atacand (22,473 reports)

Browse all side effects of Atacand:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Metastatic neoplasm:

Metastatic neoplasm (601 drugs)

Browse all the conditions that are associated with Metastatic neoplasm:

Metastatic neoplasm (516 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on candesartan cilexetil (the active ingredients of Atacand) and Atacand (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.